Series A  ·  2026
← → navigate  ·  G overview  ·  ESC close
Slide Navigator
G · ESC TO CLOSE
Series A Investment Opportunity
Lumati

Reduce. Restore.
Reach 1 Billion Lives.

Building the longevity economy. Clinical. Consumer. AI.

OUR WHY

People have lost trust in the medical system. They’ve been misdirected, channeled, and failed by a model that profits from sickness. Lumati was born out of personal passion — a commitment to support our families, our communities, and a generation seeking a better way.

Our greatest wealth is our health.

FEATURED IN FITT INSIDER · SPA BUSINESS · LONGEVITY.TECHNOLOGY · YAHOO FINANCE
LUMATI HOLDINGS, INC. · CONFIDENTIAL · APRIL 2026
What We’re Hearing

Modern Life Is Making Us Sicker

People are tired of band-aids. They want to know what actually works — and who’s listening.

400% more over-50s since 1970. Healthcare treats symptoms. Longevity is the only US category where spending is still rising.

WELLNESS ECONOMY
$6.8T
Global wellness market
Growing 10% annually. Longevity is the fastest-expanding segment.
+10%/yr
DEEP DIVE ↗
50+ DEMOGRAPHIC
$8.3T
Spending power of 50+ population
400% increase since 1970. By 2050, 2.1B people over 50 globally.
+400%
DEEP DIVE ↗
CONSUMER INTENT
57%
Ready to spend more on wellness
The only US consumer category with growing spending intent.
57%
DEEP DIVE ↗
THE CRISIS — WHY NOW
1 in 2
will get cancer — toxins accelerate it
60%
of adults have cellular breakdown
1 in 5
face brain health decline
85%
are nutrient depleted
0.04%
of spend goes to prevention
41%
of millennials spend on wellness monthly
25%
are maximalist optimizers
+19.5%
wellness real estate growth
ONLY
growing US consumer category
TAM
SAM
SOM
$42M
$6.8T–$10T TAM — Global Wellness Economy
$9.3B SAM — Addressable across 7 revenue lines
$42M SOM — Bottoms-up verified (units × price × locations) · 0.45% SAM captured
$42M base case — just 0.45% of SAM · 99.5% untouched
Our 5-year projection is a fraction of the wellness economy. Licensing is upside, not baseline.
Sources: Global Wellness Institute 2024; McKinsey 2025; Fitt Insider 2026; SNS Insider 2026; CDC 2024; CMS 2024; Gallup 2025.
Market Inflection

The Window Is Open

Six converging forces in six weeks. Regulatory alignment, capital concentration, and macro reframing all landed at once — and Lumati is the only integrated clinical-grade platform positioned to capture the full stack.

§
REGULATORY ALIGNMENT
EPA + HHS microplastics commitment
April 2026 — federal alignment for the first time. Validates HemoDetox burden-reduction category as policy, not curiosity.
Fitt Insider Issue 381 · Apr 3 2026
PEPTIDE THAW
FDA prepping to lift peptide restrictions
RFK / HHS reclassification path active. Ruby’s peptide protocol moves from edge feature to category-defining benefit.
Fitt Insider Issues 376, 380 · Mar 2026
LONGEVITY AS POLICY
+$408B US GDP per year of healthspan
$27T long-term · 1.72M lives saved by 2050. Silver Linings Bio reframes longevity from flex to public-health imperative.
Fitt Insider Issue 383 · Apr 10 2026
$
CAPITAL CONCENTRATION
$4B Q1 2026 digital-health funding
Megadeal wave concentrating into wellness and longevity. Against this backdrop, a $10M Series A reads as efficient.
Rock Health · Fitt Insider Issue 384 · Apr 14 2026
COMP VALUATIONS
Category pricing at record highs
WHOOP $10.1B · Function $2.5B · Neko Health $400M · Playlist+EGYM $7.5B. Lumati’s $73M pre reads conservative.
Fitt Insider Issues 363, 369, 380
8
LONGEVITY MACRO
$8T annual longevity spend by 2030
GLP-1 alone projected $200B/yr · longevity eating the $10T wellness stack from the inside.
UBS · Fitt Insider Issue 361 · Nov 11 2025
THE CONVERGENCE
Regulatory + capital + macro + comp pricing all turned in our direction inside 60 days. Integrated clinical-grade platforms with the full stack win the next cycle — no competitor owns the complete layer cake.
2026 IS THE YEAR
Tracked against 46 issues of Fitt Insider (Jun 2025 – Apr 2026) · Lumati Market Pulse · full provenance in data room
The Vision

1 Billion Healthy Lives by 2035

We built what people asked for. Mind, body, spirit — from flagship to home.

LONGEVITY = ECONOMIC POLICY
One year of added healthspan = +$408B US GDP · $27T long-term · 1.72M lives saved by 2050
Silver Linings Bio 2026
HEALTH OPTIMIZATION
ACCELERATED RECOVERY
COMPLEX CASES
Lumati
FLAGSHIP
Destination Hubs
POWERED CLINICS
Licensed Partners
RECHARGE NETWORK
Portal Locations
LUMATI HOME
Equipment & Supplements
EDUCATION & APP
AI-Powered Health OS
CLICK ANY NODE FOR DETAILS
THE ECOSYSTEM
Lumati Flagship
Full-service flagship centers
Powered Clinics
Licensed clinical partners
Recharge Network
Portal locations worldwide
Lumati Home
Equipment & supplements
Education & Lumi App
AI-powered health OS
5
LAYERS
5
OWNED CLINICS
50+
PARTNER PIPELINE
200+
TREATMENTS
$42M
2030 TARGET
The Science

8 Cellular Targets · 5 Principles

Hypoxia
Cellular oxygen deprivation
LEARN MORE ↗
Mitochondrial Dysfunction
Impaired energy production
LEARN MORE ↗
Misfolding Proteins
Aggregation & toxicity
LEARN MORE ↗
Impaired Autophagy
Cellular recycling failure
LEARN MORE ↗
Shortened Telomeres
Accelerated aging clock
LEARN MORE ↗
Chronic Inflammation
Immune dysregulation
LEARN MORE ↗
Apoptosis & Senescence
Zombie cells accumulate
LEARN MORE ↗
Epigenetic Drift
Gene expression decay
LEARN MORE ↗
ANCIENT WISDOM · MODERN SCIENCE

Modern medicine hacks the body but ignores the raw inputs. We focus on the physics of health — removing impediments in cellular energy production and giving you the raw ingredients for your nature to flow and flourish.

Light
Light
Sunlight to Red Light+
EXPLORE ↗
Water
Water
Living water & molecular H₂
EXPLORE ↗
Sound
Sound
Ancient bowls to neural entrainment
EXPLORE ↗
Frequency
Frequency
Earth’s pulse to PEMF
EXPLORE ↗
Earth
Earth
Nutrition, grounding & homeostasis
EXPLORE ↗
Complementary medicine is the 2nd fastest-growing wellness sector globally through 2030. — Global Wellness Institute 2024
Clinical Framework

Four Steps to Cellular Restoration

Read. Reduce. Rebuild. Nourish. At the cellular level.

It starts with the brain — the first organ to benefit from a cleaner, better-nourished cell.

NLS
STEP 1

READ

The Marrow of Life

NLS scan, 3D dental imaging, bone marrow & metabolic analysis, cognitive biomarkers. Scanning the marrow — the cellular origin of every immune cell, red blood cell, and platelet in the body.

CLICK FOR DETAILS ↗
HemoDetox
STEP 2

WEED

Subtractive Medicine

OroDetox, HemoDetox, INUSpheresis, and chelation reduce pathogen and toxin burden before restoration.

CLICK FOR DETAILS ↗
Exosomes
STEP 3

SEED

Targeted Cellular Support

Exosomes, BioRegen, peptides, and targeted supplements rebuild at the cellular level.

CLICK FOR DETAILS ↗
Recharge Portal Room
STEP 4

FEED

Ongoing Cellular Nourishment

15-min Recharge Portal sessions: Red Light+, PEMF, H₂, sound therapy, and bioresonance.

CLICK FOR DETAILS ↗
Published Case Study · Third-Party Validated

The Science Behind the Portal

mescreen™ Mitochondrial Function Blood Test · UC San Diego & NASA · 100-Day Controlled Study

+89%
Mitochondrial Energy · 60 days
+107%
Metabolic Efficiency Ratio · 30 days
+21%
Retained After 40-Day Washout
MITOCHONDRIA ENERGY SCORE
3x/week Recharge Portal Sessions
38
Day 0
Low
51
Day 30
Optimal
72
Day 60
High
46
Day 100
40d off
KEY FINDING
Energy remained in Optimal range 40 days after stopping — suggesting lasting mitochondrial adaptation via AMPK/SIRT1 activation and Nrf2-mediated ROS reduction.
Hamblin 2016 · Ohta 2012 · Lau 2012 · López-Otín 2013
TARGETED WELLNESS OUTCOMES
Longevity
Sleep & Stress
Energy & Fatigue
Mental Clarity
Brain Fog
Injury Recovery
Pain Management
Vision
Fertility
Metabolic Balance
Immune Balance
Cellular Resilience
X
XPRIZE HEALTHSPAN · $101M COMPETITION
Recharge Portal selected for Arizona State University’s XPRIZE Healthspan research protocol via Smart Fit Method.
VIEW FULL STUDY ↗
† Individual results vary. Outcomes referenced reflect partner research protocols and peer-reviewed studies — not claims of medical treatment. These statements have not been evaluated by the FDA. Lumati products and protocols are not intended to diagnose, treat, cure, or prevent any disease.
Subtractive Medicine

Reduce Before You Restore

Others add. We subtract. Clear the terrain, then restore.

OroDetox Procedure
ORODETOX

Cleaning the Mouth

Hidden oral infections implicated in cardiovascular, immune & inflammatory burden

Cavitation Surgery — necrotic jawbone & hidden infection remediation
Safe Extraction — mercury amalgam + root canal removal
Cone-Beam CT — 3D imaging reveals what X-rays miss
Systemic Integration — dental + functional medicine
HemoDetox Treatment
HEMODETOX
#1 REVENUE DRIVER

Cleaning the Blood

Advanced burden reduction through blood filtration — IP-backed & scalable across hospital networks

Dual-Target Filtration — metals, PFAS, microplastics + pathogens; CTCs in some cases
200+ Sessions — environmental burden reduction + resilience support
Clinical Programs — Long COVID + Lyme pilot studies, US hospital launch
IP Strategy — proprietary filter tech for defensible moat
68-75%
Gross Margin
200+
Treatments
$8M
2030 Rev
THE SILENT BURDEN
Everyday exposure to toxins, plastics & pathogens accelerates aging. The body cannot clear these alone.
$165-293B
Mold & Mycotoxin Burden
133M
US Adults · Chronic Burden
CATEGORY VALIDATORS
Circulate Health $12M (Khosla) · Cambiotics €4M PFAS · PolyGone $4M · MoldCo $8M · EPA + HHS microplastics commitment Apr 2026
FEATURED · FITT INSIDER · DEC 2025
† Filtration targets vary by filter type and patient case; CTC capture documented in specific cases. Individual results vary. These statements have not been evaluated by the FDA. HemoDetox is not intended to diagnose, treat, cure, or prevent any disease. ‡ MoldCo × Fitt Insider 2025 Economic Burden Report. Category raises from public announcements 2025–2026. Lumati named alongside Numenor & Blueprint in Fitt Insider Issue 365 "Clean Slate" (Dec 9 2025).
Precision Health Operating System

Lumi: Your Personalized Digital Twin

v1.0 LIVE IN APP STORE | v2.0 · Q3 2026

Lumi learns your biology in real time — biomarkers to protocols, clinic to home.

Precision Protocols
AI adapts your protocol to your biology in real time
Predictive Intelligence
Spots patterns before symptoms appear
Personalized Education
Learn why each modality matters for your cells
Adaptive Nutrition v2
Meal analysis calibrated to your metabolism
Flagship Clinical Centers

The Lumati Flagship

Physician-led. Full READ / WEED / SEED / FEED protocol under one roof.

Lumati Flagship Tijuana — NewCity Medical Plaza
OPERATIONAL
CLICK TO EXPLORE ↗

Tijuana, Mexico

Opened Oct 2024

4-step protocol · 30+ modalities · physician-led · 2024

Full Protocol 30+ Modalities Physician-Led Clinical Research
Lumati HQ Encinitas
HQ · OPERATIONAL
CLICK TO EXPLORE ↗

Encinitas, California

$5.49M Revenue (2025)

Headquarters and proving ground. The model every expansion replicates. $2.21M Q1 2026 revenue.

HQ 7 Revenue Lines 12 FTE Proven Model
30+
MODALITIES
4
STEP PROTOCOL
$45K
AVG PROGRAM
5-14
DAY PROGRAMS
Hub
TRAINING CENTER
Consumer Ecosystem

Lumati Home

Clinical-grade products. App-connected protocols. Results that compound between visits.

Lumati Green, Red & Gold
SUPPLEMENTS
Lumati Red · Green · Gold
Clinical-grade nutraceuticals prescribed in-clinic, delivered monthly via auto-ship subscription.
Recurring Revenue 83% Gross Margin
Lumati Red Light+ LED Face Mask
DEVICES
Red Light+ Face Mask
630nm + 850nm · LED photobiomodulation
Molecular Hydrogen
DEVICES
Molecular Hydrogen
H₂ water, inhalation & immersion therapy
Lumati Detect Microplastics Test Kit
DIAGNOSTICS
NAMED · FITT INSIDER
Lumati Detect
At-home saliva test kit · syncs to Lumi
Named alongside Numenor & Blueprint · Fitt Insider Dec 2025
2ND SKU COMING · AT-HOME MOLD TEST
Lumi App — Connected Ecosystem
CONNECTED ECOSYSTEM
Lumi App
BioMetrics · BioReset · BioRecharge · Marketplace
9+
PRODUCTS
5
CATEGORIES
83%
BEST GM
24/7
APP CONNECTED
shop.lumati.com
SHOP NOW ↗
GTM & Traction

Flywheel In Motion

Revenue live. Clinics deploying. Portals shipping. Every deal accelerates the next.

$5.49M
+111% YoY
2025 Revenue (Live) · Q1 ’26: $2.21M
$1.0M
$2.7M
$5.49M
’23
’24
’25
50+
Clinic Pipeline
32
Units Deployed (Q1 '26)
200+
HemoDetox Treatments
EXECUTION MILESTONES
Achieved 2026 Roadmap
Lumati Founded
2024
$5.49M FY Rev
Dec ’25 (A)
XPRIZE Selection
Feb ’26 (A)
$2.21M Q1
Mar ’26 (A)
+$262K NI Apr
Apr ’26 (A)
7 Legacy/VIP Apr
Apr ’26 (A)
ARPA-H STOMP
H2 ’26 (P)
Series A Close
Q3 ’26 (P)
$12.8M Rev
Dec ’26 (P)
$42M Run-Rate
2030 (P)
CAPITAL CONTEXT · Q1 2026 digital health funding $4B (Rock Health via Fitt Insider Issue 384) · WHOOP $10.1B (Mar 2026, Issue 380) · Function $2.5B (Nov 2025, Issue 363) · Playlist+EGYM $7.5B · Lumati $10M ask reads efficient
Competitive Moat

The Lumati Fortress

No competitor owns the full stack.

Lumati
ECOSYSTEM
🏥
Flagship
Flagship hubs
Powered Clinics
50+ pipeline
Recharge
32 units deployed
🏠
Home
Consumer HW
📱
Lumi App
AI health OS
SIX POWERFUL MOATS
🔐
Proprietary Protocol IP
READ/WEED/SEED/FEED — years of R&D, impossible to reverse-engineer
DETAILS ↗
🌐
Compounding Network Effects
Each clinic & portal amplifies value — partners become recruiters
DETAILS ↗
🧠
AI Data Flywheel
Lumi captures every interaction — new entrants start from zero
DETAILS ↗
🔒
Deep Switching Costs
Clinics embed protocols, software, supply chain — can’t leave
DETAILS ↗
Regulatory & Clinical Moat
HIPAA, IRB studies, XPRIZE — clinical evidence takes years
DETAILS ↗
🏦
Capital & Infrastructure
$40M+ to replicate · hardware + clinical ops + 198K-LOC LOS ($20–30M IP)
DETAILS ↗
NETWORK EFFECT IN ACTION — KEY REFERRAL PARTNERS
Stephen A. Smith
Media & Celebrity
TAP FOR BIO ↗
CUSTOMER
Gary Brecka
Ultimate Longevity Clinic
77M reach · runs on Lumati equipment
Dr Mark Hyman
Functional Medicine KOL
TAP FOR BIO ↗
Ben Greenfield
Fitness & Longevity
TAP FOR BIO ↗
Steve Harvey
Media & Lifestyle
TAP FOR BIO ↗
Fountain Life
Longevity Clinic Network
TAP FOR BIO ↗
ExThera Medical
HemoDetox Technology
TAP FOR BIO ↗
Dr Minkoff
Integrative Medicine Pioneer
TAP FOR BIO ↗
† Sequel Brands launched Ultimate Longevity Clinic with Gary Brecka & Lifeforce targeting 300–900 franchise locations (Fitt Insider "Clean Slate" Dec 9 2025). Brecka is an active Lumati equipment customer.
The Landscape

Who We’re Up Against — and Why We Win

Every major wellness-longevity vertical is now funded. None owns the full stack. Q1 2026 saw $4B in digital-health megadeals — the capital is flowing, but the integrated clinical-grade platform is still open.§

RUBY · LONGEVITY PACKAGE
Concierge · $150K+ · in-clinic depth
Function Health
$298M · $2.5B val (Nov 2025)
Labs + AI. No clinical floor. No peptides.
Twin Health
$53M · $950M val
Metabolic digital twin. Single-condition focus.
Blueprint (Johnson)
$60M
Consumer protocol · no clinical layer
Lifeforce / Midi / Wisp
$50M+
DTC hormone/peptide. No in-clinic depth.
LUMATI DELTA
Only full-stack: labs + genetics + body comp + peptides + IV + HemoDetox + 10-day protocol under one roof.
RECHARGE POD · HOSPITALITY
Multi-modal · hotel-ready · 15-min reset
Ammortal
$160K retail chamber
PEMF + red light + H2 + sound. Not FDA-cleared.
Regenesis (Djokovic)
Celebrity pod
Single-athlete brand. No licensing play.
Aescape
32K sessions delivered
Robotic massage only. Single modality.
Lanserhof / Therme
€95M · $1B JV
Destination only. Can’t scale to hotels.
LUMATI DELTA
FDA-cleared Red Light+ · H2 Analytics-certified · $60K retail vs. $160K · placement-ready for Marriott/Fairmont.
ZIVA + LUMATI OS
Voice AI · clinic ops · 198K LOC
Counsel Health
$25M Series A
96% resolution, 2-min response. Patient-facing only.
Ultralight (ex-Vibrant)
$9.3M seed
AI-native OS for preventative clinics. Pre-launch.
Ambient Scribes
Abridge / Nuance / Athelas
Clinical note-taking only. No ops layer.
Daxko Elevate
Turnkey bolt-on
Gym-floor software. No clinical protocol.
LUMATI DELTA
Already shipped: 198K LOC · $20–30M IP · voice intake + clinic ops + compliance + cross-sell engine in one stack.
HEMODETOX · UPSIDE
Burden reduction · not in base case
Circulate Health
$12M Khosla
TPE longevity affiliate model. No integrated protocol.
Cambiotics
€4M (Collaborative Fund)
PFAS-clearing probiotics. Ingredient, not protocol.
MoldCo / PolyGone
$8M / $4M
Diagnostic/filter only. No treatment arm.
Numenor · Blueprint
Named with Lumati
At-home MNP diagnostics · no clinical stack
LUMATI DELTA
Diagnostic + filtration + Recharge + clinic in one stack · featured alongside the above in Fitt Insider Dec 2025.
CAPITAL CONTEXT
Q1'26 digital health $4B · WHOOP $10.1B · Function $2.5B · Playlist+EGYM $7.5B · Hims–Eucalyptus $1.15B · Lumati $10M ask = top Rule-of-40 efficiency
§ Rock Health Q1 2026 Funding Overview; comp rounds from Fitt Insider Issues 359, 363, 365, 380, 384 (2025–2026). Lumati positioning and differentiators reflect current product stack and certifications. HemoDetox is upside-only in base case until FDA clearance.
Leadership, Governance & Strategic Capital

Team, Board & Advisors

EXECUTIVE TEAM
David Perez
Founder & CEO
5 ventures built · healthcare operator
Ruta Laukien
Chairwoman
GrayBella · Bear Stearns · Duke JD/MBA/LL.M.
Samuel Whiting
Chief Strategy Officer
WHOOP · UCLA Sports Med
Gunnar Link
Chief Financial Officer
M&A · 3 company sales
Erol Erturk
Chief Technology Officer
Purdue · AI/software 10+ yrs
Carrie Carda, MD
Functional Oncology Advisor
FACOG · 34 yrs clinical · A4M
BOARD OF DIRECTORS
DR
David Roth
Strategic Advisor
Eugene Chrinian
Founder, Ashley NE
David Kasteler
Regen Med · 4 Exits
+12
Extended Team
Clinic Ops · Labs · Coaching · Hospitality
VIEW FULL TEAM ↗
BOARD OF ADVISORS
Lucas Winthrop
$2.6B AUM
Wylie Aronow
Yuga Labs / BAYC
Skyler Ditchfield
GeoLinks Co-Founder
Todd Wanek
CEO, Ashley Furniture
Austin Singleton
OneWater Marine (ONEW)
MEDICAL LEADERSHIP
Jigar Gandhi, DDS
Biological Dentistry
DDS · SUNY Stony Brook · 15+ yrs
Dr Daniel Roney
Longevity Medical Director
25+ yrs · cancer survivor
Dr Guillermo Castillo
Regenerative Medical Director
20+ yrs functional med
Dr Greg Lane
Clinical Director
Founding member · 31+ yrs
$12B+ combined EV · 155+ countries reached · NYSE public co. leadership · 19 leaders + advisors · $5B+ brands built (Vuori, BAYC, Ashley)
Financials · Bottoms-Up Verified

Path to $42M

49.3%
CAGR
$1.27M (P)
2026 Net Income
Day 1 (P)
Profitable
+111% YoY · Q1 ’26: $2.21M
$1.0M
’23
$2.7M
’24
$5.49M
’25
268
Invoices
164
Customers
7
Rev Lines
2030 BASE CASE
$42M
62%
GM
$12.2M
EBITDA
29%
Margin

Revenue Bridge — $5.49M → $42M

Memberships Equipment HemoDetox E-Comm Other
0.45% of SAM ($9.3B) 0.0006% of TAM ($6.8T) Licensing = cherry on top
COMPS · WHOOP $10.1B · Function $2.5B · Playlist+EGYM $7.5B · Q1’26 digital health $4B (Fitt Insider Issues 380, 363, 384)
Full Income Statement
5-year P&L with EBITDA & net income — opens live model
Margin Profile
GM%, EBITDA%, net income trajectory
7 REVENUE LINES
Memberships
$11M
73.6% GM — recurring, highest-margin line
Equipment
$9M
55% GM · 34% from clinical cross-sell
HemoDetox
$8M
68-75% GM
E-Commerce
$7M
50% GM
BioRegen · Wellness · NLS
3 LINES
$7M
61–84% GM · clinical-services cluster
EBITDA WALK
-$1.3M
2025
$2.47M
2026 ✓ 19%
$3.2M
2027
$5.5M
2028
$8.8M
2029
$12.2M
2030
Profitable from Day 1. No additional fundraising required after Series A. 29.1% EBITDA margin by 2030.
Bottoms-up model: units × price × locations. Verified from invoice-level detail. Full model in data room.
Unit Economics · Verified

Revenue & Margin by Division

Seven revenue lines. Every COGS figure verified by our Chief Financial Officer.
3.5x
Revenue Growth
62%
2030 GM
$26M
Gross Profit ’30

Revenue by Division

$ IN MILLIONS
DIVISION 2025A 2026E 2028E 2030E GM%
Memberships $1,050 $3,800 $7,500 $11,000 73.6%
Equipment $2,125 $3,500 $6,000 $9,000 55.1%
HemoDetox $1,300 $2,000 $5,200 $8,000 68-75%
E-Commerce $354 $700 $3,200 $7,000 50%
BioRegen · Wellness · NLS 3 LINES $850 $2,000 $4,500 $7,000 61-84%
Total $5,487 $12,800 $26,400 $42,000 62%
All figures in $000s. 2025A reflects Fiscal Year close. GM% at Year 2+ maturity. Seven verified revenue lines grouped as five categories above. Source: invoice-level detail + Labs forensic audit + membership COGS matrix.

Revenue Mix by Year

Mem Equip HD E-Com Other

2030 Revenue Mix

$42M
2030
Memberships 26%
Equipment 21%
HemoDetox 19%
E-Commerce 17%
BioRegen + Wellness + NLS 17%

2030 Gross Margin by Line

Memberships
73.6%
HemoDetox
68-75%
BioRegen
71%
Equipment
55.1%
E-Commerce
50%
%
REVENUE DIVERSIFICATION
Seven revenue lines. No line over 26% of total. Shifts from equipment (37%) to recurring services (79% by 2030).
MARGIN EXPANSION
Gross margin expands from 54.2% (2025A) to 62% (2030E) as Year 2+ memberships (73.6% GM) dominate mix.
$
GROSS PROFIT TRAJECTORY
2030 gross profit of $26M on $42M revenue. EBITDA reaches $12.2M at 29.1% margin.
Bottoms-up model: units × price × locations. Verified from invoice-level detail + Labs forensic audit + membership COGS matrix. Full model in data room.
Unit Economics · Forensic Audit

Proven at the Unit Level

Hardware Unit Margins (Labs Forensic Audit)

PRODUCT RETAIL COGS NET GM%
LG10 Pod (bundled) $125-130K $61,631 $68,369 55.1%
PRO10 Pod $89,900 $46,000 $43,900 48.8%
Recharge Portal $60,000 $22,826 $37,174 62.0%
LW10 Standalone $24,000 $14,000 $10,000 41.7%
LW8 $9,000 $3,500 $5,500 61.1%

GROSS MARGIN BY PRODUCT

Recharge Portal
62.0%
LW8
61.1%
LG10 Pod
55.1%
PRO10 Pod
48.8%
LW10
41.7%
$0
Paid CAC
$162K
4-Category LTV
42–62%
Hardware GM
HEMODETOX PRICING
Per-filter unit economics — 68-75% gross margin
Per Filter
$25K retail / $20K member
COGS
$6,343 per filter
3-Filter Full
$75K retail / $60K member
GM Retail
74.6%
GM Member
68.3%
MEMBERSHIP LTV
$150K Year 1 revenue
Year 2+ base: $75K (73.6% GM on renewals). Year 1 COGS includes services + equipment placement + NLS scans. 1.7 new members/mo verified since Oct 2025.
SERVICE LINES — GM%
83.5%
Clinic & Wellness
Highest GM line
77%
BioRegen
$48K retail
50%
E-Commerce
Supplements
CAC
ZERO PAID ACQUISITION
100% referral-driven. $0 paid CAC across the audited Q1 2026 customer base. Oldest cohort 30+ months. 0 member departures across 2,000+ member-months of data.
GM
MARGIN TRAJECTORY
GM expands from 54.2% (2025A) to 62% (2030E) as Year 2+ memberships (73.6% GM) dominate mix.
$68K
HARDWARE AS GATEWAY
LG10 Pod yields $68K gross profit. Equipment opens the door — 34% of clinical customers cross-sell to memberships & services.
Source: Labs forensic audit (32 units deployed), invoice verification, Product/Service COGS Matrix. Financial Model — April 2026.
Verified Invoice Detail

Customer Economics

20% of customers engage multiple service lines — and generate 44% of revenue.

3.5x
Revenue multiplier — multi vs single category
34%
of equipment revenue from clinical patients
65 days
Average time to 2nd service line
32
Multi-category customers (20% of base)
REVENUE BY ENGAGEMENT DEPTH
CATEGORIESCUSTOMERSAVG REVVS SINGLE
1 category139 (85%)$35,699baseline
2 categories18 (11%)$124,7823.5x
3 categories4 (2%)$133,5033.7x
4 categories3 (2%)$162,4814.6x
CROSS-SELL CONVERSION (VERIFIED)
ENTRY POINTRATEAVG TIME#1 DEST
BioRegen40.0%1.7 moEquipment
HemoDetox28.9%1.5 moEquipment
Wellness Pkg26.7%1.8 moEquipment
Equipment8.1%1.7 moHemoDetox
The #1 cross-sell destination from every clinical service is equipment. 34% of all equipment revenue comes from clinical patients.
REAL CUSTOMER JOURNEYS (ACTUAL DATA)
BioRegen → H₂ → PRO10 → LG10 → LW10 Portal
$446K
HemoDetox → Membership → Pod → Portal → Bath
$398K
Membership → H₂ → Filter → NLS
$278K
$1.275M
2027 LOCKED ARR
17 Legacy Members × $75K Year 2 — all members signed Year 2 renewal in contract · 0% churn across 2,000+ member-months · 73.6% GM · members include Fortune-tier executives, $5B+ brand founders, and A-list entertainers
Lumati Intelligence

Operating System & AI Platform

Not a clinic chain. A longevity platform. 198K lines of code. $20–30M IP at licensing scale.

198K
Lines of code across 996 files
14
Major systems in production
$1.5M+
Replacement cost (8-10K hours)
$20-30M
IP value at licensing scale
WITHOUT LOS (MANUAL)
Weekly exec brief
Analyst pulls data from 7 systems, 4+ hours
Cross-sell identification
Staff remembers who bought what, misses 80%+
Team health monitoring
Manager gut feel, issues surface at exit
Compliance review
Lawyer reviews every asset, $500+/hour
WITH LUMATI OS (TODAY)
Weekly exec brief
Auto-generated Monday 6am, zero labor
Cross-sell identification
Flags every trigger in 65 days, routes to sales
Team health monitoring
Ziva detects flight risk, burnout, blockers weekly
Compliance review
30+ FDA/FTC rules auto-scanned before publish
$1M OF SERIES A FUNDS AI PLATFORM
Replaces 3-5 FTE of back-office ops ($240-400K/year savings). Payroll scales from $1.7M to $6.6M while revenue scales 3.5x. Sub-linear OpEx is the moat.
CATEGORY CAPITAL · Ultralight (ex-Vibrant Practice) raised $9.3M seed to build the same thing for clinics (Fitt Insider Issue 384, Apr 14 2026). Lumati already has 198K LOC shipped. Counsel Health at $25M benchmarks ambient admin AI at 96% resolution + 2-min response (Issue 358).
Scenario Analysis

Base Case is Conservative

Five scenarios. We underwrite the base. Upside: $70M revenue, $420M implied.

LEAN
$26M
2030 Revenue
Raise $4-5M
Revenue-funded
Partner + 1 hub
$6.5M EBITDA (25%)
CONSERVATIVE
$32M
2030 Revenue
2nd flagship only
25% slower membership
2026 NI+
$7M EBITDA (22%)
UNDERWRITE
BASE CASE
$42M
2030 Revenue
2nd flagship + 2 hubs
1.7 new members/mo
2026 NI+
$12.2M EBITDA (29%)
UPSIDE
$55M
2030 Revenue
2nd flagship + 3 hubs by 2029
COFEPRIS → FDA path
2026 NI+
$16M EBITDA (29%)
FULL POTENTIAL
$70M
2030 Revenue
5 owned + 75-100 licensed
Clinic licensing upside
2026 NI+
$30M EBITDA (43%)
KEY METRICS BY SCENARIO
METRIC LEAN CONSERVATIVE BASE UPSIDE FULL
2030 Revenue $26M $32M $42M $55M $70M
2030 EBITDA $6.5M $7M $12.2M $16M $30M
EBITDA Margin 25% 22% 29% 29% 43%
New Locations Flagship + 1 Flagship only Flagship + 2 hubs Flagship + 3 hubs 5 + 75-100 licensed
Capital Required $4-5M $8M $10-11M $15M $15M
Implied Valuation (6x rev) $156M $192M $252M $330M $420M
WHY $30M EBITDA IS CREDIBLE
Two-engine model: Clinic ops ($55M @ 36% EBITDA = $20M) + Licensing ($15M @ 75% GM = $10.4M) + LOS savings ($2M). Toast, Mindbody, athenahealth routinely hit 40-50% EBITDA at scale.
SIGNED DEALS — UPSIDE STACK
Not in base case. Activates as each channel comes online.
INUSPHERESIS
+$20–27M
Proxima Health partner · US 2027
EVOLT CHANNEL
+$6–10M*
Signed · supplements + hardware · 3M audience
MEMBER ACCEL
+$5–8M
4/mo vs 1.7/mo pace
Combined: +$31–45M stacks on base case
* Evolt range directional — forecast pending sell-through data
LICENSING PIPELINE SIGNAL
50+ clinics in discussions. 3 LOIs expected Q3 2026. First licensed clinic targeted Q2 2027. Demand gated by platform productization.
Regulatory Catalyst · Not in Base Case

HemoDetox Expansion Pathways

Two routes beyond Encinitas. COFEPRIS Mexico in process; US FDA clearance is the long-term pathway.

EARNED MEDIA · Lumati named alongside Numenor Health and Blueprint in Fitt Insider “Clean Slate” Blood Bath feature (Issue 365, Dec 9 2025)
IN PROCESS

COFEPRIS Mexico

2026-2027 timeline
HOW IT WORKS
Mexican FDA equivalent. Long COVID clinical trial documentation on file. Regulatory counsel engaged. Approval de-risks the US FDA pathway.
Pricing$15-20K / filter
Volume15-25 patients/mo
Clinics10+ MX partners
2030 HD Rev$18-26M
Medical tourism premium pricing vs US
LONG-TERM UPSIDE

FDA Cleared

2028-2030 timeline
HOW IT WORKS
FDA clearance transforms HemoDetox from wellness offering to reimbursable medical procedure. Unlocks insurance, hospital partnerships, 10x addressable market.
Pricing$15-25K / filter
ChannelInsurance reimbursed
Partners20+ hospitals
2030 HD Rev$25-35M
ExThera has FDA EUA — precedent exists
Apr 2026: EPA + HHS commit to microplastics remediation (Fitt Insider Issue 381) — federal alignment for the first time
CATEGORY SURFACE
Post-approval upside†
3.7B HSV-1 · 65M US Long COVID+Lyme · 100% adults microplastics · category scale in billions.
CATEGORY $ 2025
Circulate $12M · Cambiotics €4M · PolyGone $4M · MoldCo $8M
CLINICAL PIPELINE ALREADY BUILT
49 referring physicians · 97 long COVID patients waiting for any pathway to access treatment. Not speculative demand.
EVIDENCE ON FILE
Mescreen case study +89% mitochondrial energy · PNOE metabolic collab · XPRIZE research at ASU. Data room ready.
IMPACT ON 2030
Each pathway adds $7-27M to 2030 revenue. Base case assumes $8M HD. Any single pathway activation = meaningful upside.
Risk Management

Risks & Mitigations

Regulatory. Operational. Market. What we watch and how we mitigate.

Regulatory — HemoDetox
HIGH PRIORITY
Risk: FDA action could restrict or slow HemoDetox protocols.
Mitigation: Wellness framing · COFEPRIS Mexico in process · HD upside only in base case · FDA regulatory track active.
New Location Underperformance
MEDIUM
Risk: Each location at 50% = $2–3M less revenue by 2030.
Mitigation: Staged opening · 2nd flagship proves the model before hub expansion.
Membership Growth Slows
MEDIUM
Risk: 1.0 vs 1.7 new members/mo = $3M less by 2030.
Mitigation: 6 proposals outstanding · multi-location expansion grows pool · 0% observed churn.
Equipment Sales Volatility
MONITORED
Risk: Large B2B deals are lumpy. Quarters can swing $500K.
Mitigation: Diversifying into hospitality channels · recurring service revenue (memberships 26% of 2030 rev).
Key-Person Concentration
MEDIUM
Risk: Heavy reliance on Perez, Laukien, Whiting for strategy, governance, deal flow.
Mitigation: 198K-LOC OS captures playbooks · ESOP retention · independent board (Roth, Chrinian, Kasteler) · documented C-suite succession.
Supplier Concentration
MEDIUM
Risk: HemoDetox filter supply currently routes through ExThera Medical as primary source.
Mitigation: Dual-sourcing in progress · proprietary Lumati filter IP as long-term moat · HD not in base case until FDA · COFEPRIS diversifies regulatory surface.
Data Security & Compliance
MEDIUM
Risk: 198K-LOC OS handles PHI across HIPAA scope — larger attack surface than consumer-only.
Mitigation: HIPAA-compliant architecture · vendor BAAs · SOC2 roadmap · security review per Ziva/Lumi release · no PHI in marketing analytics.
Hospitality Partner Churn
MONITORED
Risk: Recharge pod revenue depends on multi-partner pipeline (Marriott, Alila Marea, La Valle, Smart Fit).
Mitigation: 50+ clinic pipeline · diversified luxury/wellness/fitness verticals · plug-and-play Recharge · no partner >20% of hospitality rev.
REGULATORY
COFEPRIS + FDA regulatory track. Wellness framing. Diversified revenue.
EXECUTION
$1M→$2.7M→$5.49M (+111% YoY), Q1 ’26: $2.21M, profitable from 2026.
DIVERSIFICATION
Seven revenue lines, no customer >7%, 37%→79% services.
Valuation & Capital Structure

$73M Pre-Money is Conservative

Five methods point to $57–90M. Rule of 40 score: 152 — top 1% of SaaS.

VALUATION FRAMEWORK
METHOD METRIC MULTIPLE VALUE
Forward Revenue (2026E) $12.8M 5.7x $73M
Q1 2026 Annualized $14.2M 5x $71M
Trailing Revenue (Fiscal Year 2025) $5.49M 10x $57M
2028E EBITDA $5.5M 15x $83M
Rule of 40 Score 152 Top-decile $80-90M
Public Comp WHOOP $1.1B RR 9.2x $10.1B
RECOMMENDED 6x Forward Rev $73M
PREMIUM FACTORS
Profitable from 2026 (rare at Series A) · Rule of 40: 152 (top 1%) · 7 diversified revenue lines, no customer >7% · LOS tech moat ($20-30M IP value) · 49.3% CAGR backed by Q1 actuals
WHOOP public comp: $10.1B valuation / $1.1B run rate ≈ 9.2x (Fitt Insider Issue 380, Mar 31 2026)
POST-SERIES A CAP TABLE · $73M PRE
David Perez (CEO)
44.5%
SAFE Investors
20.9%
Series A ($10M)
8.1%
Vested Team
6.6%
Wylie Aronow
4.9%
ESOP (new)
15.0%
Founder + Team retain 56% control. ESOP refreshed to 15% at Series A close (David Perez (CEO) and Ruta Laukien (Chairwoman) approved 2026-05-11). $3.7M debt non-convertible — stays as debt, no dilution.
SUB-LINEAR OPEX — THE MOAT
2025
81%
OpEx/Rev
2030
36%
OpEx/Rev
Payroll scales $1.7M → $6.6M while revenue scales 3.5x. Without the LOS platform, we’d need 8-10 more FTE for back-office ops. Every $1 of Series A buys $3.3+ in annual revenue by Year 3.
Series A Investment Opportunity

The Ask

“We are not building for a quarter. We are building for generations.”

$5.49M revenue · Q1 ’26 $2.21M invoiced · Profitable from Day 1 · 268 audited invoices · 7 revenue lines · 1 billion healthy lives by 2035
Series A
$10M
Pre-Money: $73M
PRIOR CAPITAL RAISED
Conv. Note $3.7M | SAFEs $4.4M | Total $8.1M

Use of Proceeds

$10M
25% Flagship
15% Sales & Marketing
15% AI + Staffing
17% R&D
13% E-Commerce
15% Working Capital

Where Your Capital Goes

SIZED TO PLAN · NO RE-RAISE
$2.5M
2nd Flagship Build-out
Second flagship facility + clinical staffing
$1.5M
Sales, Marketing & Brand
Google NBS, Detect category, Legacy referral
$1.5M
AI Platform + Staffing
Lumati OS / Lumi build + key hires
$1.7M
R&D + Hardware Portal V2
Portal V2 next-gen design + certification
$1.3M
E-Commerce Scale-up
Brand + supplement portfolio scale
$1.5M
Working Capital + Reserves
Inventory + payroll runway + debt service
KEY MILESTONES POST-CLOSE
Q2
Series A Close · Q2 2026
$10M raised, 100% of proceeds to growth
Q4
Hospitality + Network Expansion · Q4 2026
Recharge Network deployments + Lumati Network clinic licensees
’26
Profitable Year 1 · FY2026
$1.27M Net Income · $2.47M EBITDA (17.1%)
’28
Free Cash Flow Positive · 2028
No additional fundraising required
TARGET RETURN
10x
12% post-close · 3x base · 5x upside · +licensing
2030 BASE
$42M
Revenue · 6x mult → $252M exit
“My functional age markers improved significantly after the flagship protocol. The portal changed my daily performance — I feel sharper, sleep deeper, think clearer. I brought my whole family.”
— FLAGSHIP MEMBER · ENCINITAS
† Individual results vary. Reflects mescreen Mitochondrial Function panel post-protocol improvements and partner-research benchmarks. Not a claim of medical treatment, diagnosis, cure, or age reversal.
Clinical Network · Upside Scenario

Three-Tier Licensing Model

Not in base case. $15M revenue by 2030 at 75-100 licensed clinics — the EBITDA multiplier.

1
Level One · Outpost

Equipment Only

Turnkey Lumati hardware bundles. 30–90 day ramp. No ongoing rev share.
Avg Order Value$80K
COGS / Net60% / 40%
Rev ShareNone
SupportInstall + training
VIEW FULL TERMS ↗
2
Level Two · Spokes

Equipment + Protocols

Hardware + protocol IP license + clinical playbooks + Lumi platform access.
Upfront$25K
Monthly$10K+ SaaS
Rev Share5%
SupportProtocol + coaching
VIEW FULL TERMS ↗
3
Level Three · Hubs

Full Stack + Equity

Co-branded flagship. Full operating stack, MD training, lifetime upside.
Equity Stake10%+
Operating StackFull
Co-BrandYes
SupportMD training + ops
VIEW FULL TERMS ↗
$10M+Pipeline
50+Clinics in Pipeline
10–20Live by Q4 2026
Equipment Catalyst · Cherry on Top

Franchise & Hospitality Pipeline

Not in base case. $52-108M addressable across four franchise/hospitality channels. Gary Brecka is already a Lumati equipment customer; Discovery Land Company conversation just opened.

$52-108M
Total addressable across all channels
$28-65M
Preferred vendor scenario
900+
Franchise locations in pipeline
GEISLER · BRECKA

Ultimate Longevity Center

Franchise biohacking studio concept
Locations (3 yr)300-900
Equipment/unit1 Portal @ $60K
Opportunity$14-41M
Preferred vendor75%
KEY INSIGHT
Sequel Brands launched Ultimate Longevity Clinic with Brecka + Lifeforce (Fitt Issue 365, Dec 2025). Brecka is an active Lumati equipment customer. Geisler runs Xponential — standardizes one vendor per category.
LUXURY HOSPITALITY

Ritz-Carlton Properties

Already using PBM technology
Hotels100+
Equipment/unit1-2 @ $60-130K
Opportunity$3-13M
Preferred vendor50%
KEY INSIGHT
Ritz uses TheraLight 360 at Beaver Creek & Amelia Island. Recharge Portal is superior with Mescreen data. Alila Marea (Marriott) is already a Lumati revenue-share partner.
GLOBAL SPA NETWORK

Marriott Managed Spas

500+ spas globally
Properties468 residences
Equipment/unit1 Portal @ $60K
Opportunity$11M
Preferred vendor40%
KEY INSIGHT
Alila Marea (Marriott brand) already deployed Recharge Portal with rev-share. Marriott + Lefay JV Mar 2026 (Fitt Issue 381) — Lefay becomes Marriott’s 39th brand and first dedicated luxury wellness brand, confirming the wellness-resort thesis.
PRIVATE COMMUNITIES

Discovery Land Company

Ultra-high-net-worth residential clubs
Properties30+ global
StatusIn Discussions
ScopeWellness platform
OpenedApr 2026
KEY INSIGHT
Introduction Apr 27 via Bret Gossett (Lumati Encinitas client) directly to John Frager at Discovery Land. Conversation: integrate Recharge, Red Light+, H2 + diagnostic stack into Discovery properties.
WHY PREFERRED VENDOR STATUS IS ACHIEVABLE
Franchise standardization = winner-take-most. One equipment decision covers ALL locations. Portal V2 R&D ($1.7M in Series A) is purpose-built for high-volume, multi-location deployment.
Lumati

The Best Medicine
is Knowledge.

We are not building for a quarter. We are building for generations. 1 billion healthy lives by 2035 — not as a projection, as a promise.

$10M
Series A
$73M
Pre-Money
49.3%
CAGR
152
Rule of 40
David Perez
Founder & CEO
+1 (858) 414 4811
Samuel Whiting
Chief Strategy Officer
+1 (413) 262 9257
Lumati Foundation: 10% Pre-tax Revenue to community programs
Patient. Principled. Transformational.
Due Diligence

Access the Data Room

Financial models, clinical research, legal documents, and operational details available for qualified investors.

Enter Data Room
CONFIDENTIAL · NDA REQUIRED
Legal Notice

Disclaimer and Risk Factors Disclosure Statement

THE FOLLOWING FINANCIAL MODELS AND/OR PROJECTIONS HAVE BEEN USED BY THE MANAGEMENT OF LUMATI HOLDINGS, INC. (THE "COMPANY") IN PLANNING THE FUTURE OPERATIONS OF THE COMPANY. THEY ARE NECESSARILY SPECULATIVE IN NATURE AND SHOULD NOT BE VIEWED AS PROJECTIONS OF THE FUTURE FINANCIAL PERFORMANCE OF THE COMPANY. WHILE MANAGEMENT BELIEVES THAT THE OBJECTIVES OF THE PITCH DECK HAVE BEEN PREPARED IN GOOD FAITH, BASED UPON EXISTING CONDITIONS AND REASONABLE ASSUMPTIONS, THERE CAN BE NO ASSURANCE THAT SUCH OBJECTIVES WILL BE REALIZED. THE ACTUAL RESULTS OF THE OPERATION OF THE COMPANY MAY AND PROBABLY WILL VARY FROM THE FOLLOWING FINANCIAL MODELS OR PROJECTIONS; AND SUCH VARIATIONS MAY BE MATERIAL. THE COMPANY'S PERFORMANCE AND THE COMPANY'S ABILITY TO MEET ITS OBJECTIVES, AS DESCRIBED IN OUR MATERIALS, MAY BE AFFECTED BY MANY FACTORS, INCLUDING NUMEROUS FACTORS THAT ARE BEYOND THE COMPANY'S CONTROL.

THE PITCH DECK AND BUSINESS PLAN IS NOT A STATIC DOCUMENT BUT RATHER A CONTINUING PROCESS WHICH CHANGES OVER TIME. IT SHOULD BE ANTICIPATED THAT THE COMPANY'S BUSINESS, OPERATIONS, MANAGEMENT, FINANCIAL CONDITION, AND PITCH DECKS WILL CHANGE DURING THE COURSE OF THE COMPANY'S OPERATIONS. THE PROJECTED FINANCIAL INFORMATION IN THESE MATERIALS WAS NOT PREPARED TO COMPLY WITH GUIDELINES OF THE SECURITIES AND EXCHANGE COMMISSION OR THE AMERICAN INSTITUTE OF CERTIFIED PUBLIC ACCOUNTANTS. THE PROJECTIONS ARE NOT INTENDED TO FOLLOW GENERALLY ACCEPTED ACCOUNTING PRINCIPLES. NEITHER OUR ACCOUNTANTS NOR OUR LEGAL COUNSEL HAVE COMPILED, AUDITED, PREPARED OR CONTRIBUTED TO THE PROJECTIONS OR THE UNDERLYING ASSUMPTIONS. NONE OF THESE PARTIES EXPRESS AN OPINION WITH RESPECT TO THE PROJECTIONS.

THE FOLLOWING ADDITIONAL DISCLAIMERS APPLY: LUMATI SERVICES AND ITS PRODUCTS ARE NOT INTENDED TO CURE, TREAT, HEAL, OR PREVENT ANY DISEASES OR ILLNESSES. THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THE INFORMATION PRESENTED ON OUR SOCIAL MEDIA AND WEB SITE IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY; IT IS NOT MEANT TO SUBSTITUTE FOR MEDICAL ADVICE OR DIAGNOSIS PROVIDED BY YOUR PHYSICIAN OR OTHER MEDICAL PROFESSIONAL. DO NOT USE THIS INFORMATION TO DIAGNOSE, TREAT OR CURE ANY ILLNESS OR HEALTH CONDITION. IF YOU HAVE, OR SUSPECT THAT YOU HAVE A MEDICAL PROBLEM, CONTACT YOUR PHYSICIAN OR HEALTH CARE PROVIDER.

CONFIDENTIAL / HIPAA INFORMATION: THIS DOCUMENT, INCLUDING ANY ATTACHMENTS, MAY CONTAIN CONFIDENTIAL INFORMATION AND IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY FOR WHICH IT IS INTENDED. IF YOU ARE NOT THE INTENDED RECIPIENT, ANY DISCLOSURE, COPYING, USE, OR DISTRIBUTION OF THE INFORMATION INCLUDED IN, AND ACCESSED THROUGH, THIS DOCUMENT IS PROHIBITED BY FEDERAL AND STATE LAW.